Ali T, Usman R, Shah S, Parvez A, Anwar S, Muneer Z
Cancer Control. 2024; 31:10732748241271714.
PMID: 39110525
PMC: 11307363.
DOI: 10.1177/10732748241271714.
Trovarelli G, Sbaraglia M, Angelini A, Bellan E, Pala E, Belluzzi E
Clin Orthop Relat Res. 2024; .
PMID: 38170705
PMC: 11124741.
DOI: 10.1097/CORR.0000000000002960.
Shen T, Wang H, Tang B, Zhu G, Wang X
RNA Biol. 2023; 20(1):223-234.
PMID: 37221841
PMC: 10210855.
DOI: 10.1080/15476286.2023.2216562.
Scholl J, Weber A, Dias C, Lima V, Grun L, Zambonin D
Purinergic Signal. 2023; 20(1):47-64.
PMID: 36964277
PMC: 10828327.
DOI: 10.1007/s11302-023-09931-4.
Thamim M, Agrahari A, Gupta P, Thirumoorthy K
Molecules. 2023; 28(5).
PMID: 36903561
PMC: 10005488.
DOI: 10.3390/molecules28052315.
Mitochondrial Alterations in Prostate Cancer: Roles in Pathobiology and Racial Disparities.
Vikramdeo K, Sharma A, Anand S, Sudan S, Singh S, Singh A
Int J Mol Sci. 2023; 24(5).
PMID: 36901912
PMC: 10003184.
DOI: 10.3390/ijms24054482.
An Overview: The Diversified Role of Mitochondria in Cancer Metabolism.
Liu Y, Sun Y, Guo Y, Shi X, Chen X, Feng W
Int J Biol Sci. 2023; 19(3):897-915.
PMID: 36778129
PMC: 9910000.
DOI: 10.7150/ijbs.81609.
Low expression of isocitrate dehydrogenase 1 (IDH1) R132H is associated with advanced pathological features in laryngeal squamous cell carcinoma.
Shayanfar N, Zare-Mirzaie A, Mohammadpour M, Jafari E, Mehrtash A, Emtiazi N
J Cancer Res Clin Oncol. 2022; 149(8):4253-4267.
PMID: 36063222
DOI: 10.1007/s00432-022-04336-z.
Targeting Energy Metabolism in Cancer Treatment.
Kubik J, Humeniuk E, Adamczuk G, Madej-Czerwonka B, Korga-Plewko A
Int J Mol Sci. 2022; 23(10).
PMID: 35628385
PMC: 9146201.
DOI: 10.3390/ijms23105572.
The Interplay Between Prostate Cancer Genomics, Metabolism, and the Epigenome: Perspectives and Future Prospects.
Singh R, Mills I
Front Oncol. 2021; 11:704353.
PMID: 34660272
PMC: 8511631.
DOI: 10.3389/fonc.2021.704353.
Decoding the heterogeneous landscape in the development prostate cancer.
Segura-Moreno Y, Sanabria-Salas M, Varela R, Mesa J, Serrano M
Oncol Lett. 2021; 21(5):376.
PMID: 33777200
PMC: 7988715.
DOI: 10.3892/ol.2021.12637.
The presence of TIM-3 positive cells in WHO grade III and IV astrocytic gliomas correlates with isocitrate dehydrogenase mutation status.
Sorensen M, Nielsen O, Reifenberger G, Kristensen B
Brain Pathol. 2020; 31(3):e12921.
PMID: 33244787
PMC: 8412096.
DOI: 10.1111/bpa.12921.
Androgen Receptor Signaling and Metabolic and Cellular Plasticity During Progression to Castration Resistant Prostate Cancer.
Uo T, Sprenger C, Plymate S
Front Oncol. 2020; 10:580617.
PMID: 33163409
PMC: 7581990.
DOI: 10.3389/fonc.2020.580617.
Wild-Type IDH Enzymes as Actionable Targets for Cancer Therapy.
Bergaggio E, Piva R
Cancers (Basel). 2019; 11(4).
PMID: 31010244
PMC: 6520797.
DOI: 10.3390/cancers11040563.
Epigenetic Enzyme Mutations: Role in Tumorigenesis and Molecular Inhibitors.
Han M, Jia L, Lv W, Wang L, Cui W
Front Oncol. 2019; 9:194.
PMID: 30984620
PMC: 6449417.
DOI: 10.3389/fonc.2019.00194.
Genome-Based Classification and Therapy of Prostate Cancer.
Angeles A, Bauer S, Ratz L, Klauck S, Sultmann H
Diagnostics (Basel). 2018; 8(3).
PMID: 30200539
PMC: 6164491.
DOI: 10.3390/diagnostics8030062.
IDH1R132H Promotes Malignant Transformation of Benign Prostatic Epithelium by Dysregulating MicroRNAs: Involvement of IGF1R-AKT/STAT3 Signaling Pathway.
Zhang L, Qi M, Feng T, Hu J, Wang L, Li X
Neoplasia. 2018; 20(2):207-217.
PMID: 29331887
PMC: 5767912.
DOI: 10.1016/j.neo.2017.12.001.
The emerging role and targetability of the TCA cycle in cancer metabolism.
Anderson N, Mucka P, Kern J, Feng H
Protein Cell. 2017; 9(2):216-237.
PMID: 28748451
PMC: 5818369.
DOI: 10.1007/s13238-017-0451-1.
Altered Mitochondrial Signalling and Metabolism in Cancer.
Chattopadhyay E, Roy B
Front Oncol. 2017; 7:43.
PMID: 28373964
PMC: 5357656.
DOI: 10.3389/fonc.2017.00043.
Translational and clinical implications of the genetic landscape of prostate cancer.
Spratt D, Zumsteg Z, Feng F, Tomlins S
Nat Rev Clin Oncol. 2016; 13(10):597-610.
PMID: 27245282
PMC: 5030163.
DOI: 10.1038/nrclinonc.2016.76.
